AstraZeneca wins UK approval for Seroquel XL in major depression
AstraZeneca has been given the go-ahead in the UK to market its once-daily antipsychotic product Seroquel XL (quetiapine fumarate) as an add-on treatment of major depressive episodes in patients with major depressive disorder (MDD).
The green light in the UK follows European Commission approval of the new indication last month. Seroquel is already sold for a number of indications including schizophrenia and bipolar disorder, and generated sales of around $4.9 billion for AstraZeneca last year.
AstraZeneca had originally hoped to develop Seroquel as a first-line treatment for major depression, but had to scale backs its ambitions after running into opposition from regulators on the grounds that Seroquel's side effects were too worrisome to support use in such a broad population.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze